Topical lidocaine for neuropathic pain in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2014, Pages

  Derry, Sheena ^a   Wiffen, Philip J ^a   Moore, R Andrew ^a   Quinlan, Jane ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; PLACEBO; LOCAL ANESTHETIC AGENT;

ADULT; ANALGESIA; APPLICATION SITE REACTION; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; INTENTION TO TREAT ANALYSIS; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN INTENSITY; POST TRAUMATIC NEURALGIA; POSTHERPETIC NEURALGIA; POSTSURGICAL NEURALGIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SKIN MANIFESTATION; SKIN REDNESS; SYSTEMATIC REVIEW; TRIGEMINUS NEURALGIA; WORLD HEALTH ORGANIZATION; META ANALYSIS; NEURALGIA; NEURALGIA, POSTHERPETIC; PAIN, POSTOPERATIVE; TRIGEMINAL NEURALGIA;

ADULT; ANESTHETICS, LOCAL; HUMANS; LIDOCAINE; NEURALGIA; NEURALGIA, POSTHERPETIC; PAIN, POSTOPERATIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGEMINAL NEURALGIA;

EID: 84912007181     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010958.pub2     Document Type: Review

References (85)

1. Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clinical Drug Investigation 2009;29(6):393-408. [DOI: 10.2165/00044011-200929060-00003]3000643
2. Bischoff JM, Petersen M, Uçeyler N, Sommer C, Kehlet H, Werner MU. Lidocaine patch (5%) in treatment of persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled, crossover trial. Anesthesiology 2013;119(6):1444-52. [DOI: 10.1097/ALN.0b013e3182a2a243]3000645
3. Cheville AL, Sloan JA, Northfelt DW, Jillella AP, Wong GY, Bearden Iii JD, et al. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Supportive Care in Cancer 2009;17(4):451-60. [DOI: 10.1007/s00520-008-0542-x]3000647
4. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80(3):533-8. [DOI: 10.1016/S0304-3959(98)00244-9]3000649
5. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clinical Journal of Pain 2002;18(5):297-301. 3000651
6. Rowbotham MC, Davies PS, Galer BS. Multicenter, double-blind, vehicle-controlled trial of long term use of lidocaine patches for postherpetic neuralgia [abstract 184]. Abstracts of the 8th World Congress of the International Association for the Study of Pain (Vancouver, British Columbia, Canada, August 17-22). 1996:274. 3000652
7. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clinical Journal of Pain 2008;24(1):51-5. [DOI: 10.1097/AJP.0b013e318156db26]3000654
8. Kanai A, Suzuki A, Kobayashi M, Hoka S. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. British Journal of Anaesthesia 2006;97(4):559-63. [DOI: 10.1093/bja/ael180]3000656
9. Kanai A, Kumaki C, Niki Y, Suzuki A, Tazawa T, Okamoto H. Efficacy of a metered-dose 8% lidocaine pump spray for patients with post-herpetic neuralgia. Pain Medicine 2009;10(5):902-9. [DOI: 10.1111/j.1526-4637.2009.00662.x]3000658
10. Kanai A, Segawa Y, Okamoto T, Koto M, Okamoto H. The analgesic effect of a metered-dose 8% lidocaine pump spray in posttraumatic peripheral neuropathy: a pilot study. Anesthesia and Analgesia 2009;108(3):987-91. [DOI: 10.1213/ane.0b013e31819431aa]3000660
11. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106(1-2):151-8. [DOI: 10.1016/S0304-3959(03)00317-8]3000662
12. Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. Journal of Neurology 2005;252(6):677-86. [DOI: 10.1007/s00415-005-0717-z]3000663
13. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Annals of Neurology 1995;37(2):246-53. [DOI: 10.1002/ana.410370216]3000665
14. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65(1):39-44. [DOI: 10.1016/0304-3959(95)00146-8]3000667
15. A Randomized, Double-Blind, Crossover Study Comparing Pliaglis™ (Lidocaine and Tetracaine) Cream 7%/7% to Placebo Cream When Applied for 60 Minutes in the Treatment of Patients With Postherpetic Neuralgia. http://clinicaltrials.gov/ct2/show/NCT00609323 (accessed 5 February 2014) 2014. [NCT: NCT00609323]3000669
16. Lidocaine 5% Medicated Plaster for the Topical Treatment of Localized Chronic Postoperative Neuropathic Pain. http://clinicaltrials.gov/ct2/show/NCT01155986 (accessed 5 February 2014) 2014. [NCT: NCT01155986]3000671
17. Tajti J, Szok D, Vécsei L. Topical acetylsalicylic acid versus lidocaine for postherpetic neuralgia: results of a double-blind comparative clinical trial. Neurobiology (Bp) 1999;7(2):103-8. 3000673
18. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions. http://clinicaltrials.gov/ct2/show/NCT00904202 (accessed 5 February 2014) 2014. [NCT: NCT00904202]3000675
19. Lidocaine patches in postoperative and posttraumatic neuropathic chronic skin pain - A prospective, randomized, double-blinded, placebo-controlled, parallel, multicentre, investigator initiated study according to clinical guidelines. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015415-41 (accessed 5 February 2014) 2014. [Eudract number: 2009-015415-41]3000677
20. Efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000347-28 (accessed 5 February 2014) 2014. [Eudract number: 2012-000347-28]3000679
21. Topical lidocaine for the treatment of focal peripheral neuropathic pain: response in relation to pain phenotype. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003077-26 (accessed 5 February 2014) 2014. [Eudract number: EudraCT 2012-003077-26]3000681
22. A Randomized, Double-Blind, Placebo-Controlled Trial (RDBPCT) of the Effectiveness of the Lidocaine Patch in the Management of Neuropathic Pain After Breast Cancer Surgery. ClinicalTrials.gov (accessed 5 February 2014) 2014. 3000683
23. Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain. Clinical trials.gov (accessed 5 February 2014) 2014. 3000685
24. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain 2011;152(3 Suppl):S49-64.
25. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-7.
26. Campbell BJ, Rowbotham M, Davies PS, Jacob P 3rd, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. Journal of Pharmaceutical Sciences 2002;91(5):1343-50.
27. Chronicle EP, Mulleners WM. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD003226.pub2]
28. Cochrane Pain, Palliative and Supportive Care Group. PaPaS author and referee guidance. http://papas.cochrane.org/sites/papas.cochrane.org/files/uploads/L%20-%20PaPaSAuthor%26RefereeGuidance.pdf (accessed 22 January 2013).
29. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111]
30. Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3]
31. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21.
32. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [DOI: 10.1093/ije/31.1.140]
33. Electronic Medicines Compendium. Versatis 5% Medicated Plaster. Summary of Product Characteristics. www.medicines.org.uk/emc/medicine/19291 (accessed 17 December 2013).
34. Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. Drugs 2009;69(15):2149-65. [DOI: 10.2165/11203220-000000000-00000]
35. Geborek P, Crnkic M, Petersson IF, Saxne T, South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Annals of the Rheumatic Diseases 2002;61(9):793-8. [DOI: 10.1136/ard.61.9.793]
36. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132-6.
37. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice 2008;9:26.
38. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
39. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
40. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011;152(10):2204-5.
41. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991;10:276-81.
42. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine 1996;156(6):661-6.
43. Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1-3):122-7.
44. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33.
45. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007115.pub2]
46. McQuay H, Moore R. An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 978-0192630483]
47. McQuay HJ, Smith LA, Moore RA. Chronic pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007. [ISBN: 978-1846190636]
48. Mick G, Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster - a review. Current Medical Research and Opinion 2012;28(6):937-51.
49. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097.
50. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. Neuroimaging 2007;37(Suppl 1):S80-8.
51. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16.
52. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0931092695]
53. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]
54. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9.
55. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9.
56. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4.
57. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7.
58. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2]
59. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9.
60. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32.
61. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
62. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
63. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690.
64. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94.
65. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain 2014;18(1):67-75.
66. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15.
67. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. American Journal of Medicine 2009;122(10 Suppl):S22-32.
68. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain 1994;56:127-38.
69. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
70. Sabatowski R, Hans G, Tacken I, Kapanadze S, Buchheister B, Baron R. Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia. Current Medical Research and Opinion 2012;28(8):1337-46. [DOI: 10.1185/03007995.2012.707977]
71. Sawynok J. Topical analgesics for neuropathic pain: preclinical exploration, clinical validation, future development. European Journal of Pain 2014;18(4):465-81. [DOI: 10.1002/j.1532-2149.2013.00400.x]
72. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Practice 2014;14(2):167-84. [DOI: 10.1111/papr.12054]
73. Soni A, Batra R, Gwilym S, Spector T, Hart D, Arden N, et al. Neuropathic features of joint pain: a community-based study. Arthritis & Rheumatism 2013;65(7):1942-9.
74. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266-75.
75. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia - responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150.
76. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29.
77. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281-9.
78. Tracey I. Can neuroimaging studies identify pain endophenotypes in humans?. Nature Reviews Neurology 2011;7(3):173-81.
79. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-5.
80. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155(4):654-62. [DOI: 10.1016/j.pain.2013.11.013]
81. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96.
82. Wehrfritz A, Namer B, Ihmsen H, Mueller C, Filitz J, Koppert W, et al. Differential effects on sensory functions and measures of epidermal nerve fiber density after application of a lidocaine patch (5%) on healthy human skin. European Journal of Pain 2011;15(9):907-12. [DOI: 10.1016/j.ejpain.2011.03.011]
83. Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Medical Weekly 2010;140(21-2):297-306. [DOI: smw-12995]
84. Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurologica Scandinavica 2011;123(5):295-309. [DOI: 10.1111/j.1600-0404.2010.01433.x]
85. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004846.pub2]